Skip to content
DataLookout
Menu

CA2024-LM-001NCT07098806

Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

StatusRecruiting
PhasePhase 1/2
SponsorCerenome
Primary completion (estimated)

At risk: Primary completion moved at least 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 2, 2026 to Jul 31, 2027
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Notable Phase changed: Phase 1 → Phase 1/2
    • Sponsor changed: Plus Therapeutics to Cerenome
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Maximum Tolerated Dose
Timeframe: 13 months
Dose Distribution of 186RNL
Timeframe: 13 months
Safety and tolerability of multiple dose treatment
Timeframe: 13 months

Secondary (5)

Determine the objective response rate (ORR).
Determine the overall survival (OS).
Characterize the dosimetry profile of 186RNL.
Determine neurologic progression-free survival (PFS).
Evaluate Neurologic status by NANO scale

Arms and interventions

Experimental: Multiple DosesExperimental

This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.

Drugs: 186RNL

Sites

1 site in 1 country

  • The Cancer Therapy and Research Center at UTHSCSASan Antonio, Texas, United States